ArticleCHEST pulmonary2025
Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with idiopathic pulmonary fibrosis (IPF) experience impairments in health-related quality of life (HRQL). Research Question: What is the trajectory of decline in HRQL in patients with IPF and is this influenced by patients' demographic/clinical characteristics at baseline? Study Design and Methods: The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry is a registry of patients with IPF. HRQL was assessed at enrollment and during routine clinical care using the following patient-reported outcomes (PROs): the Cough and Sputum Assessment Questionnaire, the St. George's Respiratory Questionnaire, the 12-item Short Form Survey, and the EuroQol score and visual analog scale. Trajectories of PRO scores were estimated using a mixed joint model. Associations between sex, age, FVC and diffusing capacity of the lungs for carbon monoxide (both % predicted), use of supplemental oxygen, and use of antifibrotic therapy at enrollment and trajectories of PRO scores were assessed. Results: The cohort included 957 patients. Estimated mean changes in scores over 48 months were 10.8, 7.0, 13.1, and 10.5 for the St. George's Respiratory Questionnaire total, symptoms, activity, and impact scores; -7.6 and -6.5 for the Cough and Sputum Assessment Questionnaire cough impact and symptoms scores; -2.1 and -7.0 for the 12-item Short Form Survey Mental Component Summary and Physical Component Summary scores; and -0.08 and -9.0 for the EuroQol score and visual analog scale, respectively ( Interpretation: Among patients in the IPF-PRO Registry, a range of PROs showed worsening in HRQL over 48 months. Female sex, lower age, worse lung function, and use of supplemental oxygen were associated with worse HRQL at enrollment and during follow-up. These findings suggest that interventions aimed at preserving HRQL in patients with IPF may be of particular benefit for certain groups of patients. Clinical Trial Registration: ClinicalTrials.gov; No.: NCT01915511; URL: www.clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.